Cambridge Cognition Secures £1million Contract for Phase 3 Autoimmune Disease Trial

Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, has been selected by a major pharmaceutical company to provide digital cognitive assessments for a large Phase 3 autoimmune disease clinical trial. The initial contract, starting in 2025 and running through to 2031, is valued at approximately £1 million.  The Company has previously provided services to this customer, and this represents repeat business with this global company. 

Autoimmune diseases represent a significant unmet medical need where both physical and cognitive symptoms play a critical role in disease burden. Many patients, with persistent symptoms like fatigue, joint pain, and cognitive impairment (often referred to as “brain fog”) remain underdiagnosed and untreated and this impacts quality of life¹. The decision by our client to use CANTAB®’s cognitive assessments in an autoimmune disease trial reflects an expanding recognition of the multifaceted nature of autoimmune disorders and the critical importance of considering the impact on the central nervous system.

Cambridge Cognition was selected by this existing customer due to our scientifically validated, proprietary cognitive assessments and our proven ability to deliver digital cognitive testing solutions on a global scale. Supported by an experienced clinical project management team, CANTAB® will be deployed in 16 countries and 23 languages across 245 trial sites to support this study.

Rob Baker, Joint Managing Director and Chief Operating Officer, commented:

“We view this repeat business from an existing customer as a strong endorsement of our product value and service excellence. The expanding research in autoimmune diseases is promising, positioning us to address this growing need and significantly expand our presence in the high-impact, late-stage CNS trials market. We’re encouraged by this momentum, with this major contract following shortly after last week’s £1.2m agreement for Phase 3 clinical trials in adolescents with Major Depressive Disorder.”